Analysis of Cdc2 and cyclin D1 expression in breast cancer by immunoblotting

被引：5

作者：

Ohta T. ^{[1
]}

Fukuda M. ^{[1
]}

Arima K. ^{[1
]}

Kawamoto H. ^{[1
]}

Hashizume R. ^{[1
]}

Arimura T. ^{[1
]}

Yamaguchi S. ^{[1
]}

机构：

[1] First Department of Surgery, St. Mananna University, School of Medicine, Miyamae-ku, Kawasaki 216

来源：

Breast Cancer | 1997年 / 4卷 / 1期

关键词：

Breast cancer; Cdc2; Cyclin D1; Prognosis;

D O I：

10.1007/BF02967050

中图分类号：

学科分类号：

摘要：

Cyclins and cyclin-dependent kinases may reflect the status of cell proliferation in cancer tissues. The authors sought to determine whether cdc2 and cyclin D1 are expressed in breast cancer and are useful as prognostic factors. Accumulation of cdc2 and cyclin D1 proteins was examined in 88 cases of breast cancer using immunoblotting techniques and correlations with clinicopathological factors and prognoses were investigated. Cdc2 and cyclin D1 proteins were observed in 27.3% and 75.0% of breast cancers studied, respectively. The incidence of lymph node metastasis was significantly high in cdc2/cyclin D1-double positive group and low in double negative group. On the other hand, the incidence of estrogen receptor (ER) negative cases was significantly higher in the cdc2-positive/cyclin D1-negative group. Relapsefree survival times of cdc2-positive cases were significantly shorter than those of cdc2-negative cases. The relapse-free survival times of cyclin D1-positive cases also tended to be poorer than those of cyclin D1-negative cases. Multivariate analyses revealed cdc2 as the second most significant of the prognostic variables, following lymph node status. The three-year relapse-free survival rate of cdc2/cyclin D1-double positive cases was 58.9%, whereas that of cdc2/cyclin D1-double negative cases was 100%. Cdc2 and cyclin D1 represent the status of cell proliferation in breast cancer, and may be useful in breast cancer assessment.

引用

页码：17 / 24

页数：7

共 32 条

[1]

Kallioniemi O.P., Kallioniemi A., Kurisu W., Et al., ErbB2 amplification in breast cancer analyzed by fluorescence in situ hybridization, Proc Natl Acad Sci USA, 89, pp. 5321-5325, (1992)

[2]

Borg A., Baldetorp B., Ferno M., Killander D., Olsson H., Sigurdsson H., ERBB2 amplification in breast cancer with a high rate of proliferation, Oncogene, 6, 1, pp. 137-143, (1991)

[3]

Coles C., Condie A., Chetty U., Et al., P53 mutation in breast cancer, Cancer Res, 52, pp. 5291-5298, (1992)

[4]

Runnebaum I.B., Nagarajan M., Bowman M., Soto D., Sukumar S., Mutations in p53 as potential molecular markers for human breast cancer, Proceedings of the National Academy of Sciences of the United States of America, 88, 23, pp. 10657-10661, (1991)

[5]

Isola J., Visakorpi T., Holli K., Et al., Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in nodenegative breast cancer patients, J Natl Cancer Inst, 84, pp. 1109-1114, (1992)

[6]

Hartmann L.C., Ingle J.N., Wold L.E., Farr Jr. G.H., Grill J.P., Su J.Q., Maihle N.J., Krook J.E., Witzig T.E., Roche P.C., Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer: Results from a randomized adjuvant treatment protocol, Cancer, 74, 11, pp. 2956-2963, (1994)

[7]

Lowenstein E.J., Daly R.J., Batzer A.G., Et al., The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling, Cell, 70, pp. 431-442, (1992)

[8]

Li Y., Jenkins C.W., Nichols M.A., Xiong Y., Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21, Oncogene, 9, 8, pp. 2261-2268, (1994)

[9]

Hunter T., Pines J., Cyclins and cancer II: Cyclin D and CDK inhibitors come of age, Cell, 79, 4, pp. 573-582, (1994)

[10]

Loyer P., Glaise D., Cariou S., Baffet G., Meijer L., Guguen-Guillouzo C., Expression and activation of cdks (1 and 2) and cyclins in the cell cycle progression during liver regeneration, Journal of Biological Chemistry, 269, 4, pp. 2491-2500, (1994)

← 1 2 3 4 →